High Throughput Screening (HTS) Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The high throughput screening (HTS) market size has grown rapidly in recent years. It will grow from $22.98 billion in 2024 to $25.49 billion in 2025 at a compound annual growth rate (CAGR) of 10.9%. The growth in the historic period can be attributed to increasing adoption of high-throughput screening, rising r&d spending, growing availability of funds for research, increasing healthcare spending, competitive market landscape.

The high throughput screening (HTS) market size is expected to see strong growth in the next few years. It will grow to $36 billion in 2029 at a compound annual growth rate (CAGR) of 9%. The growth in the forecast period can be attributed to increasing market size and growth rate, strategic developments by key players, rising demand for disease monitoring and drug discovery, rising prevalence of chronic diseases, growing focus towards implementation of ultra high throughput screening (UHTS) techniques. Major trends in the forecast period include technological advancements in high-throughput screening, growing focus towards implementation of ultra high throughput screening (UHTS) techniques.

The increasing prevalence of chronic diseases is anticipated to drive the growth of the high-throughput screening (HTS) market in the coming years. Chronic disease refers to a long-term health condition that typically lasts three months or more. HTS allows for the rapid screening of large numbers of chemical compounds to identify potential drug candidates aimed at specific pathways or mechanisms involved in chronic diseases, which is crucial for effective long-term management. For example, in January 2023, the U.S. National Library of Medicine reported that the number of individuals aged 50 and older in the U.S. with at least one chronic condition is projected to reach 142.66 million by 2050. Thus, the growing prevalence of chronic diseases is expected to fuel the expansion of the HTS market.

Major companies operating in the high-throughput screening market are developing innovative products, such as multimode plate readers, to better serve their customers with advanced features. A multimode plate reader (MPR) is an advanced lab tool used in high-throughput screening, analyzing biological and chemical samples in microplates by integrating multiple detection modes for diverse assays within a single platform. For instance, in February 2023, PerkinElmer Inc., a US-based MedTech company, launched the EnVision Nexus system. The EnVision Nexus system stands out as the fastest and most sensitive multimode plate reader available, explicitly designed for demanding high-throughput screening (HTS) applications to expedite drug discovery efforts. With its unique technology, including dual detectors and optimized reagents like proprietary HTRF and AlphaLISA, coupled with the latest reagent kits, the platform offers researchers unparalleled assay flexibility, accuracy, speed, and sensitivity. Equipped with walkaway convenience options such as a plate stacker for 20 or 50 plates or full automation and integration for continuous 24/7 workflow-driven operations, the EnVision Nexus system empowers researchers to efficiently screen millions of samples with unprecedented efficiency.

In December 2023, PerkinElmer Inc., a US-based MedTech company, acquired Covaris Inc. for an undisclosed amount. With this acquisition, Covaris' growth potential is anticipated to be accelerated, while PerkinElmer's existing life sciences portfolio is poised to expand into the rapidly growing diagnostics end market. Covaris Inc. is a US-based provider of high-throughput screening solutions.

Major companies operating in the high throughput screening (HTS) market are Thermo Fisher Scientific Inc., AstraZeneca Plc, Danaher Corporation, Merck Group, GE HealthCare Technologies Inc., Corning Inc., Agilent Technologies Inc., Lonza Group Ltd., Charles River Laboratories International Inc, Beckman Coulter Inc., PerkinElmer Inc., Bio-Rad Laboratories, Tecan Group Ltd., Sygnature Discovery Ltd., Luminex Corporation, Hamilton Company, Crown Bioscience Inc., HighRes Biosolutions, NanoTemper Technologies GmbH, BMG LABTECH GmbH, Axxam SpA, Reprocell Inc., BioTek Instruments Inc, Aurora Biomed Inc., Cyclica Inc., Biomat Srl, Diana Biotechnologies s.r.o.

North America was the largest region in the high throughput screening market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the high throughput screening (HTS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the high throughput screening (HTS) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The high-throughput screening (HTS) market consists of revenues earned by entities by providing services such as compound library screening, assay design and adaptation, and pilot screening. The market value includes the value of related goods sold by the service provider or included within the service offering. The high-throughput screening (HTS) market also includes sales of lab equipment and supplies, chemicals, assay development tools, and data processing software. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

High-throughput screening (HTS) is a technique employed in drug discovery and various scientific domains to rapidly assess a large number of samples for biological activity. Its purpose is to identify active compounds, antibodies, or genes that modulate specific biological pathways, thereby expediting the drug discovery process.

The main types of products and services in high-throughput screening (HTS) are consumables and reagents, instruments, software, and services. Consumables and reagents refer to the materials and chemicals used in the screening process, including sample containers, assay reagents, and other disposable items necessary for experimental procedures. The technology types are categorized into ultra-high-throughput screening, cell-based assays, lab-on-a-chip, and label-free technology, which are used in several applications such as target identification and validation, primary and secondary screening, toxicology assessment, and others. The end users include the pharmaceutical and biotechnology industries, academic and research institutes, contract research organizations, and others.

The main types of products and services in high-throughput screening (HTS) are consumables and reagents, instruments, software, and services. Consumables and reagents refer to the materials and chemicals used in the screening process, including sample containers, assay reagents, and other disposable items necessary for experimental procedures. The technology types are categorized into ultra-high-throughput screening, cell-based assays, lab-on-a-chip, and label-free technology, which are used in several applications such as target identification and validation, primary and secondary screening, toxicology assessment, and others. The end users include the pharmaceutical and biotechnology industries, academic and research institutes, contract research organizations, and others.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.